Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 01, 2024 15:00 ET | Source: Teva Pharmaceutical Industries Ltd

Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as well as Results of Real-World Analyses of UZEDY® (risperidone)

Teva’s presentation of findings from six schizophrenia studies at Psych Congress 2024 highlights its commitment to finding new innovations in neuroscienceData show TEV-'749 drug delivery technology...
September 21, 2024 04:15 ET | Source: Teva Pharmaceutical Industries Ltd

Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia

As a leader in neuroscience, Teva is committed to researching new treatment innovations that may help address unmet needs in treating schizophrenia, including TEV-‘749Currently, there is no...
February 29, 2024 11:01 ET | Source: Research and Markets

Schizophrenia Treatment Advances with Emerging Pipeline Insights Through 2024

Dublin, Feb. 29, 2024 (GLOBE NEWSWIRE) -- The "Schizophrenia - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering. This report confers a rich, panoramic view of...
February 27, 2024 11:06 ET | Source: Research and Markets

Anorexia Nervosa Treatment Advances with New 2024 Pipeline Landscape Report

Dublin, Feb. 27, 2024 (GLOBE NEWSWIRE) -- The "Anorexia Nervosa - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering. A Comprehensive Overview of Emerging...
February 14, 2024 10:19 ET | Source: Research and Markets

Olanzapine Market Report 2024 - Global Trends, Forecasts and Competitive Analysis to 2030 - Opportunities in the Bipolar Disorder and Schizophrenia Markets

Dublin, Feb. 14, 2024 (GLOBE NEWSWIRE) -- The "Olanzapine Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's offering.The global...